BioCentury | Apr 2, 2021
Management Tracks

O’Brien to head NPC; plus moves at Frontier, Araris, Montis and more

The National Pharmaceutical Council (NPC) hired John O’Brien, former senior adviser to the U.S. secretary of HHS, as president and CEO, effective June 1. Prior to his role at HHS, O’Brien served as VP of public...
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

...and autophagy inducers.Founded in 2018 based on chemoproteomics technology developed at University of California Berkeley, Frontier Medicines Corp....
...Capital, Deerfield Management, Droia Oncology Ventures, DCVC Bio, RA Capital, othersCEO: Chris VarmaPatents: Undisclosed Karen Tkach Tuzman Frontier Medicines Corp. targeted...
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...an October deal. AbbVie, Frontier enter protein degradation deal focused on cancer, immunologyAbbVie Inc. (NYSE:ABBV) and Frontier Medicines Corp....
...therapeutics to treat cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie Inc. Frontier Medicines Corp. Exelixis...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...disease and healthy contexts. UC Berkeley professor and Frontier Medicines Corp....
...Inc. Lycia Therapeutics Inc. PolyProx Therapeutics Ltd. Cedilla Therapeutics Inc. Cullgen Inc. Frontier Medicines Corp. Monte...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...the clinic. “Chemistry platform companies are enormously expensive to build,” he said, comparing HotSpot to Frontier Medicines Corp....
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...The company has begun a search for a CMO and CFO. Newly launched chemoproteomics company Frontier Medicines Corp....
...director of engagement and development at the Genetics Society of America. Jonathan Block, Associate Editor Endo International plc Frontier Medicines Corp. G1...
BioCentury | Jun 25, 2019
Finance

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

...With $67 million in series A funding, newly launched Frontier Medicines Corp. believes that by using its massive...
...of Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569) (see “M is for Chemoproteomic Momentum” ). Paul Bonanos, Associate Editor Frontier Medicines Corp....
Items per page:
1 - 7 of 7
BioCentury | Apr 2, 2021
Management Tracks

O’Brien to head NPC; plus moves at Frontier, Araris, Montis and more

The National Pharmaceutical Council (NPC) hired John O’Brien, former senior adviser to the U.S. secretary of HHS, as president and CEO, effective June 1. Prior to his role at HHS, O’Brien served as VP of public...
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

...and autophagy inducers.Founded in 2018 based on chemoproteomics technology developed at University of California Berkeley, Frontier Medicines Corp....
...Capital, Deerfield Management, Droia Oncology Ventures, DCVC Bio, RA Capital, othersCEO: Chris VarmaPatents: Undisclosed Karen Tkach Tuzman Frontier Medicines Corp. targeted...
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...an October deal. AbbVie, Frontier enter protein degradation deal focused on cancer, immunologyAbbVie Inc. (NYSE:ABBV) and Frontier Medicines Corp....
...therapeutics to treat cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie Inc. Frontier Medicines Corp. Exelixis...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...disease and healthy contexts. UC Berkeley professor and Frontier Medicines Corp....
...Inc. Lycia Therapeutics Inc. PolyProx Therapeutics Ltd. Cedilla Therapeutics Inc. Cullgen Inc. Frontier Medicines Corp. Monte...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...the clinic. “Chemistry platform companies are enormously expensive to build,” he said, comparing HotSpot to Frontier Medicines Corp....
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...The company has begun a search for a CMO and CFO. Newly launched chemoproteomics company Frontier Medicines Corp....
...director of engagement and development at the Genetics Society of America. Jonathan Block, Associate Editor Endo International plc Frontier Medicines Corp. G1...
BioCentury | Jun 25, 2019
Finance

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

...With $67 million in series A funding, newly launched Frontier Medicines Corp. believes that by using its massive...
...of Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569) (see “M is for Chemoproteomic Momentum” ). Paul Bonanos, Associate Editor Frontier Medicines Corp....
Items per page:
1 - 7 of 7